Decline depth
-25.6%
From rolling 252-day high of $28.00, 31d ago.
Past the 20% Watch threshold.
-25.6%
from rolling 252-day high of $28.00 set 2026-04-27 · 31d ago
Current
$20.84
Decline depth
-25.6%
Decline σ
5.9σ
TFC
3/5 bearish
Rolling 252-day high
Up day
Down day
Last 90 trading days · data from Alpaca
Since it joined the list
$JBIO landed on the list 2026-04-16, down 78.1% from its 52-week high that day — now down -25.6%.
That's 6.7 percentage points deeper than the day it joined.
Decline from the 52-week high as it stood on 2026-04-16 (fixed anchor) → today. Split-adjusted, Alpaca. Observed history, not a forecast.
Structural break signals
JBIO qualifies for the Watch on decline depth.
Time-frame continuity
3/5 bearish
Latest bar across daily/weekly/monthly/quarterly/yearly time frames. A bar counts as bearish when it's a 2-Down or a red 3.
Past the 3/5 Watch threshold.
Decline sigma
5.9σ
Drop from local high over the last 20 bars, expressed in units of the stock's typical daily volatility (4.08% per day).
Past the ≥4σ Watch threshold.
The structural read
What price action says about JBIO.
JBIO qualifies for the Watch on decline depth — down -25.6% from its rolling 252-day high.
Cross-confirmation: also showing 3/5 bearish time frames.
Cross-confirmation: decline sigma also reads 5.9σ over 20 bars.
Earnings on file: 2026-03-06. Tiering is unaffected by earnings dates — listings reflect price structure only.
52-week range
52W low $6.57
66.6% of range
52W high $28.00
Sector context · Healthcare
194 other Healthcare tickers are on Broken Stocks.
89
Red List
47
Amber
58
Watch
-36.0%
Median decline
Worst in sector: OPRX (-77.1%). Least-bad: MRNA (-20.1%). See all Healthcare listings →
Related — same sector
Closest decliners to JBIO
WatchRecovering
ARDX
Ardelyx, Inc.
Amber ListRecovering
DHR
Danaher Corporation
Amber List
VCEL
Vericel Corporation
WatchRecovering
DYN
Dyne Therapeutics, Inc.
WatchRecovering
VKTX
Viking Therapeutics, Inc.
WatchRecovering
NEO
NeoGenomics, Inc.
Questions about JBIO
What people ask.
Why is JBIO on Broken Stocks?
JBIO qualifies for the Watch on decline depth. It is down -25.6% from its rolling 252-day high of $28.00, set on 2026-04-27 — 31d ago.
Is JBIO a falling knife?
No. The falling-knife label usually implies a steep, severe drop — typically 30% or more from a fresh high. JBIO is down -25.6% from its 52-week high, which qualifies for the Watch tier but is shallower than the falling-knife pattern. It's an early-stage decline rather than a sharp breakdown.
Is JBIO a buy?
Broken Stocks does not issue buy or sell recommendations. The list is a rules-based technical warning system. It tracks structural decline depth and recency — not company quality, management, fundamentals, or news. Always do your own research and consult a licensed advisor.
Where is JBIO trading inside its 52-week range?
At $20.84, JBIO sits 66.6% of the way from its 52-week low ($6.57) to its 52-week high ($28.00). A reading below 25% indicates price is hugging the bottom of the range; above 75%, the top.
How fast has JBIO been declining?
The current 25.6% decline accrued over 31d, which annualizes to roughly -301.4% per year. Annualized pace is a sanity check — a 30% decline in three months is a different signal than a 30% decline over two years.
How does JBIO compare to its sector?
There are 194 other Healthcare tickers on Broken Stocks: 89 Red, 47 Amber, 58 Watch, with 108 showing recovering structural signals. Median sector decline is -36.0% — JBIO's decline is shallower than the sector median.
Does JBIO's earnings date affect its tier?
No. Tiering is decided purely by decline depth and recency of the rolling-high date. The earnings date on file (2026-03-06) is shown for reference only — listings can move tier between scans based on closing prices, regardless of fundamentals or news events.